Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Total Non-Current Liabilities (2016 - 2025)

Dexcom (DXCM) has disclosed Total Non-Current Liabilities for 16 consecutive years, with -$2.9 billion as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to -$2.9 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.9 billion, a N/A change, with the full-year FY2024 number at $4.2 billion, up 4.02% from a year prior.
  • Total Non-Current Liabilities was -$2.9 billion for Q3 2025 at Dexcom, down from $4.2 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $4.2 billion in Q4 2024 to a low of -$2.9 billion in Q3 2025.
  • A 5-year average of $832.3 million and a median of $2.5 billion in 2021 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 176.65% in 2022, then surged 315.34% in 2023.
  • Dexcom's Total Non-Current Liabilities stood at $2.5 billion in 2021, then rose by 23.23% to $3.1 billion in 2022, then grew by 29.98% to $4.1 billion in 2023, then increased by 4.02% to $4.2 billion in 2024, then plummeted by 167.87% to -$2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Total Non-Current Liabilities are -$2.9 billion (Q3 2025), $4.2 billion (Q4 2024), and -$2.4 billion (Q1 2024).